Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections
NCT02113332 on ClinicalTrials.gov · last registry update 2015-02-03
Finished August 2014, after enrolling 124 people. Primary outcome, as filed: Change in HbA1c from baseline to week 24. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Vastra Gotaland Region
- Sponsor type
- Other Gov
- Enrollment
- 124
- Started
- 2013-01
- Primary completion
- 2014-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c from baseline to week 24.
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.